A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.
Johanna Wilmink
No relevant relationships to disclose
Sil Kordes
No relevant relationships to disclose
Koos Zwinderman
No relevant relationships to disclose
Ron Mathot
No relevant relationships to disclose
Cornelis J. A. Punt
No relevant relationships to disclose
Dirk Richel
No relevant relationships to disclose